Literature DB >> 3792668

Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome.

L Bardram, P Thomsen, F Stadil.   

Abstract

We have investigated the gastric endocrine cells in 19 patients with the Zollinger-Ellison syndrome. Six received a long-term treatment with omeprazole, 5 one with H2 receptor antagonists and 8 had no medical treatment. Fifteen patients (79%) had hyperplasia of the endocrine cells in the oxyntic mucosa independent of treatment. The hyperplasia involved both enterochromaffin-like (ECL) and D1 cells and was positively related to the duration of disease (p less than 0.05). The duration of hypergastrinaemia was longer in the omeprazole-treated patients, but the hyperplasia was not significantly more pronounced in these patients. Gastric carcinoid tumours consisting mainly of ECL cells are rare in man and are most often seen in states of hypergastrinaemia such as chronic atrophic gastritis. It has seldomly been reported in Zollinger-Ellison patients; but now, when potent antisecretory drugs make it possible to avoid total gastrectomy, a raised incidence might result, and an increased attention to this aspect seems appropriate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3792668     DOI: 10.1159/000199387

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  15 in total

1.  U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group.

Authors:  J E Valenzuela; R G Berlin; W J Snape; T L Johnson; B I Hirschowitz; J Colon-Pagan; R S Morse; J Petrozza; G M Van Deventer; A Cagliola
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

2.  Gastric enterochromaffin-like (ECL) cells in hypergastrinaemic duodenal ulcer disease.

Authors:  M Coupe; H Rees; C J Springer; A E Bishop; J A Morris; J M Polak; J Calam
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

Review 3.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

Review 4.  Use of omeprazole in patients with Zollinger-Ellison syndrome.

Authors:  H Frucht; P N Maton; R T Jensen
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

Review 5.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

6.  Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas.

Authors:  Melanie L Richards; Paul Gauger; Norman W Thompson; Thomas J Giordano
Journal:  World J Surg       Date:  2004-06-16       Impact factor: 3.352

7.  Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment.

Authors:  G Cadiot; T Lehy; P Ruszniewski; S Bonfils; M Mignon
Journal:  Dig Dis Sci       Date:  1993-07       Impact factor: 3.199

8.  Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome.

Authors:  T Lehy; G Cadiot; M Mignon; P Ruszniewski; S Bonfils
Journal:  Gut       Date:  1992-09       Impact factor: 23.059

9.  Gastrin receptor genes are expressed in gastric parietal and enterochromaffin-like cells of Mastomys natalensis.

Authors:  M Asahara; Y Kinoshita; H Nakata; Y Matsushima; Y Naribayashi; A Nakamura; T Matsui; K Chihara; J Yamamoto; A Ichikawa
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

Review 10.  Omeprazole. Gastrin and gastric endocrine cell data from clinical studies.

Authors:  R G Berlin
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.